BMRN

BioMarin Pharmaceutical Inc.
CAPPED RATING

Biomarin Pharmaceutical Inc is on rare-disease therapies. It develops and commercializes pharmaceuticals for serious diseases and medical conditions.

BioMarin Pharmaceutical Inc. (BMRN) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 B- (3.1) B (3.4) B+ (3.6) C+ (2.8) D+ (1.7) B- (2.9)
2026-11-09 B- (3.1) B (3.4) B+ (3.6) C+ (2.6) D+ (1.6) B- (2.9)
2026-11-05 D+ (1.8) C+ (2.5) B+ (3.6) B- (3.1) D+ (1.7) C+ (2.5)
2026-11-04 D+ (1.8) C (2.5) B+ (3.6) B- (2.9) D+ (1.6) C (2.5)
2026-11-03 D+ (1.8) C (2.5) B+ (3.6) B- (2.9) D+ (1.6) C (2.5)
Page 1 of 2

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe